- October 19, 2009
Hydra Biosciences and Cubist Form Collaboration to Develop Novel Ion Channel Drugs for Pain Management
- May 18, 2009
Research published in PNAS by Hydra Biosciences is First Demonstration in Mammals that TRP Ion Channel Drug Can Treat Allergy-Induced Asthma
- May 15, 2009
Essential Role for TRPC5 in Amygdala Function and Fear-Related Behavior
- April 22, 2009
A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma
- April 21, 2009
Pharmacological blockade of TRPA1 inhibits mechanical firing in nociceptors
- January 20, 2009
Emerging Drug Developer: Hydra Biosciences (FierceBiotech)
- January 16, 2009
Hydra Brings in $22M in Series D to Push First Program into Clinic (BioWorld Today)
- January 16, 2009
Hydra Biosciences Reaps $22.2M Series D (Dow Jones VentureWire)
- January 16, 2009
Hydra Biosciences Raises $22M to Create New Pain Relievers With Fewer Side Effects (Xconomy)
- January 16, 2009
Hydra garners $22M for ion channel programs (FierceBiotech)
- January 16, 2009
Hydra Biosciences Raises $22 Million in Series D Financing
- October 24, 2008
Hydra Biosciences Bolsters Discovery and IP Capabilities with Key Additions to Executive Management Team
- January 2, 2008
Hydra Biosciences CEO Russell Herndon Interviewed on NECN (QuickTime movie, 7 MB)
- November 16, 2007
Hydra Biosciences Featured in Mass High Tech Article
- August 14, 2007
Hydra Biosciences Publishes Article in PNAS Demonstrating that TRPA1 Mediates Formalin-Induced Pain
- August 7, 2007
Hydra Biosciences Announces Data Revealing the Crucial Role Played by the TRPA1 Ion Channel in a Standard Model of Pain Receptor Activation